Page-cited financials · quarter over quarter

NIH fundamentals.

▸ Extracted from the filings themselves — every figure links to the exact page it came from. Latest validated period: 2026-03-31. ← back to NIH

Headline trend

last 4 filed quarters

Metric	Q2 ’25	Q3 ’25	Q4 ’25	Q1 ’26
Revenue	—	—	—	KWD 861.1k p.5
Net profit	KWD 958.6k p.5	KWD 1.49mn p.5	—	—
Operating cash flow	—	—	—	KWD 1.28mn p.8
Total assets	KWD 57.74mn p.4	KWD 57.65mn p.4	KWD 55.81mn p.4	KWD 55.00mn p.4
Total equity	KWD 51.21mn p.4	KWD 51.36mn p.4	KWD 49.51mn p.4	KWD 48.54mn p.4

▸ Flows (revenue, net profit, operating cash flow) are the discrete quarter; balance-sheet lines are point-in-time.

latest filed period

as of 2026-03-31

cash	KWD 3,691,494	p.4
Accounts receivable and other assets	KWD 1,773,677	p.4
Inventories	KWD 733,994	p.4
Investments at fair value through profit or loss	KWD 3,372,190	p.4
Investments at fair value through OCI	KWD 16,651,834	p.4
Investments in debt instruments at amortized cost	KWD 5,786,934	p.4
Investment in associates	KWD 17,740,390	p.4
Investment properties	KWD 814,000	p.4
Property and equipment	KWD 4,437,513	p.4
total_assets	KWD 55,002,026	p.4
Bank facilities	KWD 2,168,783	p.4
Accounts payable and other liabilities	KWD 4,295,531	p.4
total_liabilities	KWD 6,464,314	p.4
Share capital	KWD 24,862,620	p.4
Share premium	KWD 2,813,184	p.4
Statutory reserve	KWD 2,107,129	p.4
Voluntary reserve	KWD 236,413	p.4
Fair value reserve	KWD 9,344,674	p.4
Treasury shares	KWD -302,428	p.4
Treasury shares reserve	KWD 373,850	p.4
Group's share in associates' reserves	KWD 754,842	p.4
Retained earnings	KWD 2,976,439	p.4
Equity attributable to the shareholders of the Parent Company	KWD 43,166,723	p.4
Non-controlling interests	KWD 5,370,989	p.4
total_equity	KWD 48,537,712	p.4
total_liabilities_and_equity	KWD 55,002,026	p.4

3-month to 2026-03-31

Net (loss)/profit for the period	KWD -650,559	p.8
Net investment loss/(income)	KWD 196,373	p.8
Share of results from associates	KWD 395,767	p.8
Depreciation and amortization	KWD 33,738	p.8
Provision for employees' end of service benefits	KWD 33,078	p.8
Finance costs	KWD 39,917	p.8
Operating gains/(losses) before changes in working capital	KWD 48,314	p.8
Accounts receivable and other assets	KWD -4,851	p.8
Financial assets at fair value through profit or loss	KWD 1,340,589	p.8
Inventories	KWD -87,846	p.8
Accounts payable and other liabilities	KWD -7,538	p.8
Employees' end of service benefits - paid	KWD -11,915	p.8
ocf	KWD 1,276,753	p.8
capex	KWD -96	p.8
Dividends received	KWD 7,125	p.8
Net cash generated from investing activities	KWD 7,029	p.8
Net changes in bank facilities	KWD 139,951	p.8
Finance costs paid	KWD -39,917	p.8
Cash dividends paid	KWD -8,190	p.8
Net cash generated from financing activities	KWD 91,844	p.8
Increase in cash and cash equivalents	KWD 1,375,626	p.8
Cash and cash equivalents at the beginning of the period	KWD 2,315,868	p.8
Cash and cash equivalents at the end of the period	KWD 3,691,494	p.8

3-month to 2026-03-31

revenue	KWD 861,143	p.5
Net investment (loss)/income	KWD -196,373	p.5
Share of results from associates	KWD -395,767	p.5
Other income	KWD 88,858	p.5
Cost of sales from operating activities	KWD 629,635	p.5
Other expenses	KWD 338,868	p.5
interest_expense	KWD 39,917	p.5
(Loss)/profit for the period before deductions	KWD -650,559	p.5
Net (loss)/profit for the period	KWD -650,559	p.5
Shareholders of the Parent Company	KWD -647,728	p.5
Non-controlling interests	KWD -2,831	p.5
Basic and diluted (loss)/earnings per share (fils)	KWD -2.64	p.5
Net (loss)/profit for the period	KWD -650,559	p.6
Group's share in associates' reserves	KWD -70,417	p.6
Change in fair value of equity investments at fair value through other comprehensive income	KWD -251,497	p.6
Group's share of other comprehensive loss of associates	KWD -1,168	p.6
Total other comprehensive (loss)/income items	KWD -323,082	p.6
Total comprehensive (loss)/profit for the period	KWD -973,641	p.6
Shareholders of the Parent Company	KWD -871,333	p.6
Non-controlling interests	KWD -102,308	p.6